Search by Drug Name or NDC
NDC 00078-0883-61 ADAKVEO 10 mg/mL Details
ADAKVEO 10 mg/mL
ADAKVEO is a INTRAVENOUS INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is CRIZANLIZUMAB.
MedlinePlus Drug Summary
Crizanlizumab-tmca injection is used to reduce the number of pain crises (sudden, severe pain that may last several hours to several days) in adults and children 16 years of age and older with sickle cell disease (an inherited blood disease). Crizanlizumab-tmca is in a class of medications called monoclonal antibodies. It works by blocking certain blood cells from interacting.
Related Packages: 00078-0883-61Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Crizanlizumab-tmca Injection
Product Information
| NDC | 00078-0883 |
|---|---|
| Product ID | 0078-0883_9f1b7498-2769-40fb-8e5c-0fd7ac9ff177 |
| Associated GPIs | 82807020702020 |
| GCN Sequence Number | 080477 |
| GCN Sequence Number Description | crizanlizumab-tmca VIAL 100MG/10ML INTRAVEN |
| HIC3 | N1H |
| HIC3 Description | SICKLE CELL ANEMIA AGENTS |
| GCN | 47334 |
| HICL Sequence Number | 046209 |
| HICL Sequence Number Description | CRIZANLIZUMAB-TMCA |
| Brand/Generic | Brand |
| Proprietary Name | ADAKVEO |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | crizanlizumab |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 10 |
| Active Ingredient Units | mg/mL |
| Substance Name | CRIZANLIZUMAB |
| Labeler Name | Novartis Pharmaceuticals Corporation |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA761128 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00078-0883-61 (00078088361)
| NDC Package Code | 0078-0883-61 |
|---|---|
| Billing NDC | 00078088361 |
| Package | 10 mL in 1 VIAL, GLASS (0078-0883-61) |
| Marketing Start Date | 2019-11-15 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |